Skip to main content

Site notifications

BIJUVA (Theramex Australia Pty Ltd)

Product name
BIJUVA
Date registered
Evaluation commenced
Decision date
Approval time
160 (255 working days)
Active ingredients
estradiol hemihydrate, progesterone
Registration type
New combination
Indication
New combination

BIJUVA 1/100 (soft capsule) is indicated for use during continuous combined hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women with an intact uterus and with at least 12 months since last menses.

Help us improve the Therapeutic Goods Administration site